Diluted earnings per share were $1.75, up from $0.05 last year; adjusted diluted earnings per share1 were $2.55, up from $2.12CHICAGO, Aug. 6, 2024 /PRNewswire/ -- Jones Lang LaSalle Incorporated (NYSE: JLL) today reported operating performance for the second quarter of 2024. Continued momentum in Resilient6 business line revenue was complemented by solid growth in Transactional6 revenues. These revenue factors, along with the benefit of recent and ongoing cost management efforts, helped deliver strong prof ...

BOLINGBROOK, Ill., Aug. 6, 2024 /PRNewswire/ -- Hyzon (NASDAQ: HYZN), a U.S.-based manufacturer and global supplier of high-performance hydrogen fuel cell systems focused on providing zero-emission power to decarbonize the most demanding industries, today announced that Management will host a conference call to discuss its second quarter 2024 earnings results at 8:30 a.m., ET, on Tuesday, August 13, 2024.Participants can join the call at 1-888-800-7840 or international callers can use 1-646-307-1856 and ent ...

BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024. Revenues increased 14.2% to $762.1 million compared to the prior year period Same-facility revenues increased 9.9%Same-facility cases increased 3.9% Net loss attributable to Surgery Partners, Inc. was $15.5 million Adjusted EBITDA was $118.3 million, repres ...

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment ...

文章核心观点 - 公司宣布现任首席运营官Jon Michael Adinolfi将于2025年1月1日接任公司总裁兼首席执行官,现任主席、总裁兼首席执行官Doug Cahill将转任执行主席,确保公司领导层和战略的连续性 [1][3][6] - 新任CEO Adinolfi表示将继续推动公司的服务和增长,实现20亿美元的销售目标 [2][3] - 现任CEO Cahill表示Adinolfi是合适的接班人,在过去5年里为公司做出了重大贡献,包括渡过疫情、供应链和通胀等挑战,并拓展了产品线和市场份额 [5][6] 公司概况 - 公司成立于1964年,总部位于俄亥俄州辛辛那提,是北美领先的五金解决方案提供商,为超过40,000家客户提供服务 [8] - 公司为家居改造和建筑项目提供创新的产品和陈列解决方案,客户包括家居改造中心、大型零售商、五金店、宠物用品店以及工业客户 [8] - 公司通过强大的分销和销售网络,为客户提供"小企业"的体验和"大企业"的效率 [8] 财务信息 - 公司于2021年上市,并在过去5年内偿还了9亿美元的债务 [5] - 公司目标是通过有机增长和并购实现20亿美元的销售额 [3] 其他 - 公司在2023年5月遭受勒索软件攻击,产生了相关直接和间接成本,但预计将收到保险赔付 [10] - 公司面临的风险包括经济不景气、供应链成本上升、激烈的市场竞争、创新能力、季节性、大客户集中度、人才招聘等 [10]

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of appro ...

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importa ...

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Salesforce, Inc. (NYSE:CRM) for potential violations of the federal securities laws. If you invested in Salesforce, you are encouraged to submit your information at https://www.bfalaw.com/cases-investigations/salesforce-inc. Why Did Salesforce's Stock Drop? On May 29, 2024, Salesforce reported its fiscal Q1 2025 financial results. In pertinent part, Salesforce's reported $9.13 b ...

Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expressionStrengthened leadership team with appointment of Kaan Certel, Ph.D., as Chief Business Officer and election of Richard N. Kender to Board of Directors CAMBRIDGE, Mass., Aug. 06, 2024 ...

文章核心观点 - 公司在2024年第二季度取得了重大进展,包括与Takeda签署了ACI-24.060的独家许可协议,获得1亿美元的预付款,并有机会获得最高21亿美元的里程碑付款[2][3][5] - 公司的多个临床和临床前项目进展顺利,包括阿尔茨海默病疫苗ACI-24.060的ABATE II期试验、帕金森病疫苗ACI-7104.056的II期试验以及NLRP3抑制剂ACI-19764的前期研究[5][7][8][11][12] - 公司在2024年第二季度的现金余额为1.752亿瑞士法郎,其中9230万瑞士法郎来自Takeda的付款,预计可维持公司运营3年[13] 根据目录分别总结 财务状况 - 公司2024年6月30日的现金余额为1.752亿瑞士法郎,包括5160万瑞士法郎的现金和现金等价物以及1.236亿瑞士法郎的短期金融资产[13] - 公司的现金余额预计可维持公司运营3年,前提是收到与ACI-35.030入组目标相关的2460万瑞士法郎里程碑付款,且没有其他里程碑付款[13] - 公司2024年第二季度的合同收入为70万瑞士法郎,主要来自与Takeda的合作[13] - 公司2024年第二季度的研发支出为1710万瑞士法郎,较2023年同期增加,主要是由于VacSYn II期试验和ABATE试验的活动增加[13] - 公司2024年第二季度的管理费用增加90万瑞士法郎至460万瑞士法郎,主要是由于业务发展和许可活动相关的法律费用以及股权激励费用的增加[13] 临床和临床前项目进展 - ACI-24.060 ABATE II期阿尔茨海默病疫苗试验入组进展顺利[7] - ACI-7104.056 VacSYn II期帕金森病疫苗试验预计在2024年下半年获得安全性和免疫原性的中期数据[8] - NLRP3抑制剂ACI-19764在前期研究中显示出良好的疗效和安全性,公司计划尽快提交IND申请[5] - 公司的其他临床前项目,如TDP-43 PET探针和α-突触核蛋白PET探针也在有序推进[11][12] 合作和里程碑 - 公司与Takeda签署了ACI-24.060的独家许可协议,获得1亿美元的预付款,并有机会获得最高21亿美元的里程碑付款[5] - 公司董事会和管理层在第二季度增持了公司股票[6]